PEPTIDE IDENTIFICATION

肽鉴定

• 批准号: 6099975
• 负责人: ROBERT W CHESTNUT
• 金额: $ 13.92万
• 依托单位: CYTEL CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-01 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6099975
• 关键词: AIDS vaccines; MHC class I antigen; affinity chromatography; antigen presenting cell; cell mediated lymphocytolysis test; clone cells; cooperative study; cytotoxic T lymphocyte; epitope mapping; genetically modified animals; human immunodeficiency virus 1; human tissue; immunization; immunotherapy; laboratory mouse; nonhuman therapy evaluation; peptide chemical synthesis; surface antigens; synthetic peptide; virus protein; AIDS vaccines; MHC class I antigen; affinity chromatography; antigen presenting cell; cell mediated lymphocytolysis test; clone cells; cooperative study; cytotoxic T lymphocyte; epitope mapping; genetically modified animals; human immunodeficiency virus 1; human tissue; immunization; immunotherapy; laboratory mouse; nonhuman therapy evaluation; peptide chemical synthesis; surface antigens; synthetic peptide; virus protein

The central goal of Project 1 is to identify peptide components from conserved regions of HIV-1 proteins which are capable of stimulating a specific, MHC class I-restricted cytotoxic T lymphocyte (CTL) response in man. This research builds upon the extensive experience of Project 1 scientists in identifying immunogenic peptides from viral and tumor antigens based on allele-specific binding motifs, binding affinity to class 1 molecules in vitro, and the ability to elicit primary CTL responses in human lymphocytes and HLA transgenic mice. This methodology will be applied to identifying putative CTL epitopes in internal and surface proteins of HIV-1. The initial focus of the research will be HLA- A2 peptides since this is the most frequently expressed allele in the general population. This work can be subsequently expanded to other alleles to provide broad population coverage. By creating a candidate pool of HIV-1-derived Cit peptides, Project 1 provides the essential foundation for further pep tide evaluation by Project 2 which will study peptide recognition by lymphocytes obtained from HIV-1 infected individuals. Thus, Project I contributes directly to the development of a peptide-based immunotherapeutic for AIDS which is the central focus of this Program.

项目1的核心目标是从 HIV-1蛋白的保守区域，能够刺激A 特异性MHC I类限制性细胞毒性T淋巴细胞（CTL）反应 在男人。这项研究基于项目1的广泛经验 从病毒和肿瘤鉴定免疫原性肽的科学家 基于等位基因特异性结合基序的抗原，结合亲和力 体外1类分子，以及引起初级CTL的能力 人淋巴细胞和HLA转基因小鼠的反应。这种方法 将应用于确定内部和内部和 HIV-1的表面蛋白。研究的最初重点将是HLA- A2肽，因为这是最常表达的等位基因 一般人口。这项工作随后可以扩展到其他 等位基因提供广泛的人口覆盖范围。通过创建候选人 HIV-1衍生的CIT肽池，项目1提供了必不可少的 通过项目2进行进一步的PEP潮汐评估基金会 从HIV-1感染的淋巴细胞识别的肽识别 个人。因此，我直接为发展 艾滋病的基于肽的免疫治疗性，这是 这个程序。